

CORRIGENDUM

In Heitmeier et al.,¹ Figure 2 was published incorrectly. In Figure 2H, the x axis currently reads "Factor X_{IIa} activity (%)" but should read: "Inhibition of FX_{Ia} activity (%)". Also, the figure legend is missing the word "activity", when describing panel 2H.

The correct figure and caption text is given below.




FIGURE 2 Effects of asundexian versus rivaroxaban on thrombus weight following FeCl₂-induced damage to the carotid artery (A), ear bleeding time (B) and gum bleeding time (C) in rabbits. Plasma concentrations of asundexian (D), inhibition of FX_{Ia} activity (E) and aPTT prolongation (F) according to asundexian dose, and correlation of plasma concentrations (G), Inhibition of FX_{Ia} activity (%) (H), and aPTT prolongation (I) with thrombus weight. Asundexian was administered as an intravenous bolus, whereas rivaroxaban was administered as an intravenous bolus followed by continuous infusion. Results are presented as individual values and median with 25th and 75th percentiles (Parts A–F). **p* < .05, ****p* < .001. aPTT, activated partial thromboplastin time; FX_{Ia}, activated coagulation factor XI.

The author regrets the error.

REFERENCE

1. Heitmeier S, Visser M, Tersteegen A, et al. Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor X_{IIa}. *J Thromb Haemost.* 2022;20(6):1400-1411. doi:10.1111/jth.15700